Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Enadenotucirev (EnAd) is a group B oncolytic adenovirus developed for systemic delivery and currently undergoing clinical evaluation for advanced cancer therapy. For differentiated carcinomas, systemic delivery would likely expose virus particles to the basolateral surface of cancer cells rather than the apical surface encountered during natural infection. Here, we compare the ability of EnAd and adenovirus type-5 (Ad5) to infect polarised colorectal carcinoma cells from the apical or basolateral surfaces. Whereas Ad5 infection was more efficient via the apical than basolateral surface, EnAd readily infected cells from either surface. Progeny particles from EnAd were released preferentially via the apical surface for all cell lines and routes of infection. These data further support the utility of group B adenoviruses for systemic delivery and suggest that progeny virus are more likely to be released into the tumour rather than back through the basolateral surface into the blood stream.

Original publication




Journal article



Publication Date





162 - 171


Adenovirus, Cell polarisation, Colorectal cancer, Oncolytic virus, Tight junctions, Tumour infiltration, Adenoviruses, Human, Antineoplastic Agents, Caco-2 Cells, Cell Line, Tumor, Cell Polarity, Colorectal Neoplasms, Epithelial Cells, HT29 Cells, Humans, Microscopy, Electron, Transmission, Oncolytic Virotherapy, Oncolytic Viruses, Receptors, Virus, Tight Junctions, Virus Internalization